MEP26608A - Aminothiazole derivatives and their use as crf receptor ligands - Google Patents

Aminothiazole derivatives and their use as crf receptor ligands

Info

Publication number
MEP26608A
MEP26608A MEP-266/08A MEP26608A MEP26608A ME P26608 A MEP26608 A ME P26608A ME P26608 A MEP26608 A ME P26608A ME P26608 A MEP26608 A ME P26608A
Authority
ME
Montenegro
Prior art keywords
receptor ligands
crf receptor
aminothiazole derivatives
aminothiazole
derivatives
Prior art date
Application number
MEP-266/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Evelyne Fontaine
Michel Geslin
Danielle Gully
Antoine Pradines
Pierre Roger
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of MEP26608A publication Critical patent/MEP26608A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/42Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
MEP-266/08A 1999-07-15 2000-07-11 Aminothiazole derivatives and their use as crf receptor ligands MEP26608A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9909144A FR2796380B3 (fr) 1999-07-15 1999-07-15 Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant
PCT/FR2000/001995 WO2001005776A1 (fr) 1999-07-15 2000-07-11 Derives d'aminothiazole et leur utilisation comme ligands des recepteurs crf

Publications (1)

Publication Number Publication Date
MEP26608A true MEP26608A (en) 2010-06-10

Family

ID=9548107

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-266/08A MEP26608A (en) 1999-07-15 2000-07-11 Aminothiazole derivatives and their use as crf receptor ligands

Country Status (36)

Country Link
US (2) US6586456B1 (de)
EP (1) EP1200419B1 (de)
JP (1) JP4949582B2 (de)
KR (1) KR100707320B1 (de)
CN (1) CN1167692C (de)
AR (1) AR024747A1 (de)
AT (1) ATE264315T1 (de)
AU (1) AU772683B2 (de)
BR (1) BR0012478B1 (de)
CA (1) CA2378792C (de)
CO (1) CO5200792A1 (de)
CZ (1) CZ300937B6 (de)
DE (1) DE60009911T2 (de)
DK (1) DK1200419T3 (de)
EA (1) EA005159B1 (de)
EE (1) EE05004B1 (de)
ES (1) ES2220504T3 (de)
FR (1) FR2796380B3 (de)
HK (1) HK1045692B (de)
HU (1) HU229069B1 (de)
IL (2) IL147282A0 (de)
IS (1) IS2314B (de)
ME (1) MEP26608A (de)
MX (1) MXPA02000545A (de)
NO (1) NO324352B1 (de)
NZ (1) NZ516397A (de)
PL (1) PL206515B1 (de)
PT (1) PT1200419E (de)
RS (1) RS50443B (de)
SI (1) SI1200419T1 (de)
SK (1) SK287069B6 (de)
TR (1) TR200200125T2 (de)
TW (1) TWI278453B (de)
UA (1) UA73125C2 (de)
WO (1) WO2001005776A1 (de)
ZA (1) ZA200200221B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001296255B2 (en) * 2000-09-21 2005-07-28 Bristol-Myers Squibb Company Substituted azole derivatives as inhibitors of corticotropin releasing factor
WO2003015777A1 (en) * 2001-08-13 2003-02-27 Lion Bioscience Ag Nr1h4 nuclear receptor binding compounds
US6993173B2 (en) 2001-10-12 2006-01-31 Duke University Methods for estimating probe cell locations in high-density synthetic DNA microarrays
EP1766014A4 (de) 2004-06-03 2008-12-10 Athlomics Pty Ltd Mittel und verfahren zur diagnose von stress
EP1781287A4 (de) * 2004-08-13 2008-02-27 Genentech Inc Thiazolbasierte inhibitoren atp-verwendender enzyme
EP1834641A1 (de) 2006-03-16 2007-09-19 Sanofi-Aventis CRF1-Rezeptorantagonisten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndromes, und/oder Übergewicht und/oder Dyslipoproteinemie
HUP0900267A2 (en) 2009-04-30 2011-03-28 Sanofi Aventis Process for preparing of thiazole amines and intermediates thereof
JP2015516979A (ja) * 2012-04-23 2015-06-18 ホルスボールマッシュマイヤー ニューロケミー ゲーエムベーハーHolsboermaschmeyer Neurochemie Gmbh Crh過剰活性を有する患者の治療に用いるためのcrhr1アンタゴニスト
GB201210686D0 (en) 2012-06-15 2012-08-01 Holsboermaschmeyer Neurochemie Gmbh V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
GB201310782D0 (en) 2013-06-17 2013-07-31 Max Planck Innovation Gmbh Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
NZ722122A (en) 2014-01-21 2020-06-26 Neurocrine Biosciences Inc Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
JP7532328B2 (ja) * 2018-12-07 2024-08-13 ニューロクライン バイオサイエンシーズ,インコーポレイテッド 先天性副腎過形成を処置するためのcrf1受容体アンタゴニスト、その医薬製剤および固体形態
JP7238130B2 (ja) * 2018-12-07 2023-03-13 ニューロクライン バイオサイエンシーズ,インコーポレイテッド 先天性副腎過形成を処置するためのcrf1受容体アンタゴニスト、その医薬製剤および固体形態
JP2022549496A (ja) * 2019-09-27 2022-11-25 ニューロクライン バイオサイエンシーズ,インコーポレイテッド Crf受容体アンタゴニストおよび使用方法
BR112022024875A2 (pt) 2020-06-10 2022-12-27 Neurocrine Biosciences Inc Antagonista de receptor crf1 para o tratamento de hiperplasia adrenal congênita

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692893B1 (fr) * 1992-06-24 1994-09-02 Sanofi Elf Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
FR2714059B1 (fr) 1993-12-21 1996-03-08 Sanofi Elf Dérivés amino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
FR2735777B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
FR2754258B1 (fr) * 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
YU1302A (sh) 2005-03-15
AR024747A1 (es) 2002-10-23
MXPA02000545A (es) 2002-07-30
SI1200419T1 (en) 2004-08-31
TR200200125T2 (tr) 2002-09-23
EE200200022A (et) 2003-04-15
BR0012478B1 (pt) 2013-10-15
CZ300937B6 (cs) 2009-09-16
PL352901A1 (en) 2003-09-22
HUP0202387A2 (hu) 2002-11-28
PT1200419E (pt) 2004-07-30
CO5200792A1 (es) 2002-09-27
DE60009911D1 (de) 2004-05-19
CA2378792C (en) 2009-11-10
NZ516397A (en) 2004-01-30
FR2796380A1 (fr) 2001-01-19
KR100707320B1 (ko) 2007-04-13
EP1200419A1 (de) 2002-05-02
EA200101234A1 (ru) 2002-08-29
HK1045692A1 (en) 2002-12-06
HK1045692B (zh) 2004-11-26
KR20020015373A (ko) 2002-02-27
JP4949582B2 (ja) 2012-06-13
US20070281919A1 (en) 2007-12-06
SK287069B6 (sk) 2009-11-05
HU229069B1 (en) 2013-07-29
AU6452100A (en) 2001-02-05
US6586456B1 (en) 2003-07-01
IL147282A0 (en) 2002-08-14
IL147282A (en) 2008-04-13
JP2003505380A (ja) 2003-02-12
CZ2002137A3 (cs) 2002-04-17
CN1167692C (zh) 2004-09-22
NO324352B1 (no) 2007-09-24
NO20020155D0 (no) 2002-01-11
SK382002A3 (en) 2002-07-02
HUP0202387A3 (en) 2004-12-28
DE60009911T2 (de) 2005-03-10
TWI278453B (en) 2007-04-11
PL206515B1 (pl) 2010-08-31
EP1200419B1 (de) 2004-04-14
ES2220504T3 (es) 2004-12-16
IS2314B (is) 2007-11-15
BR0012478A (pt) 2002-04-02
WO2001005776A1 (fr) 2001-01-25
EE05004B1 (et) 2008-04-15
IS6219A (is) 2002-01-03
ZA200200221B (en) 2003-04-30
EA005159B1 (ru) 2004-12-30
ATE264315T1 (de) 2004-04-15
NO20020155L (no) 2002-03-15
CN1370154A (zh) 2002-09-18
AU772683B2 (en) 2004-05-06
UA73125C2 (uk) 2005-06-15
RS50443B (sr) 2010-03-02
CA2378792A1 (en) 2001-01-25
DK1200419T3 (da) 2004-07-19
FR2796380B3 (fr) 2001-08-17
US8420679B2 (en) 2013-04-16

Similar Documents

Publication Publication Date Title
MEP26608A (en) Aminothiazole derivatives and their use as crf receptor ligands
MEP45308A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
YU40997A (sh) Novi oksadiazoli, postupci za njihovo pripremanje
EA200300595A1 (ru) Соединения пиперазинилпиразинов в качестве антагонистов серотонин 5-ht2 рецептора
YU87101A (sh) Derivati benzena, postupak za njihovo dobijanje i farmaceutski preparati koji ih sadrže
MXPA05010652A (es) Pirazoles sustituidos.
DE69910831D1 (de) Epothilonderivate und ihre verwendung als antitumormittel
YU11997A (sh) Laktamski derivati i njihove farmaceutske kompozicije
HRP20080664A2 (en) Substituted pyridine herbicides
ME00004B (me) Derivati pirimidina
DE60236600D1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
ES2178676T3 (es) Compuestos de pirimidina substituidos y su empleo.
NZ516599A (en) 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands
HRP20060009A2 (en) N-[3-(3-SUBSTITUTED-PYRAZOLO[1,5-a]PYRIMIDIN-7-YL)PHENYL]-SULFONAMIDES, AND METHODS RELATED THERETO
DE69712084D1 (de) Aminothiazole derivate, ihre herstellung und sie enthaltenden pharmazeutischen zusammensetzungen
NO20071922L (no) Indazoler, benzisokazoler og benzinsotiazoler og anvendelse derav som ostrogene midler
BR0016951A (pt) Derivado de fenilpiperazinil, composto, composição farmacêutica, uso do mesmo, método de tratamento
YU44301A (sh) 5ht1 antagonisti za antidepresantnu terapiju
MXPA05010651A (es) Compuestos de pirazol.
EA200000910A1 (ru) Азабициклические лиганды рецепторов 5нт1
MXPA05010650A (es) Pirazoles sustituidos.
EA200200727A1 (ru) Новые производные индола
ATE259813T1 (de) Triazolopyrimidinderivate
DE60041001D1 (de) Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien
MEP17408A (en) N-(heterocyclyl)benzene or pyridine sulphonamides as antithrombotic agents and anticoagulants